Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics to Present at the 2015 JMP Securities Life Sciences Conference
Argos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations
Independent Data Monitoring Committee Recommends Continuation of Pivotal ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma